Five Prime Therapeutics, Inc. (NASDAQ:FPRX) Files An 8-K Results of Operations and Financial ConditionItem 2.02
On August8, 2017, Five Prime Therapeutics, Inc. (the “Company”) issued a press release announcing its financial results for the quarter ended June30, 2017. A copy of the press release is furnished as Exhibit 99.1 to this Current Report on Form 8-K and is incorporated herein by reference.
The information provided in this Form 8-K, including Exhibit 99.1 hereto, shall not be deemed “filed” for purposes of Section18 of the Securities Exchange Act of 1934, as amended (the “Exchange Act”), or otherwise subject to the liabilities of that section, nor shall it be deemed incorporated by reference in any filing under the Securities Act of 1933, as amended, or the Exchange Act, except as expressly set forth by specific reference in such filing.
| Item 2.02 | Financial Statements and Exhibits. |
|
ExhibitNo. |
Description |
| 99.1 | Press release issued by the Company on August8, 2017 |
2
FIVE PRIME THERAPEUTICS INC ExhibitEX-99.1 2 d436464dex991.htm EX-99.1 EX-99.1 Exhibit 99.1 Five Prime Announces Second Quarter 2017 Results and Provides Business Update SOUTH SAN FRANCISCO,…To view the full exhibit click here
About Five Prime Therapeutics, Inc. (NASDAQ:FPRX)
Five Prime Therapeutics, Inc. (Five Prime) is a clinical-stage biotechnology company focused on discovering and developing protein therapeutics. The Company has three product candidates in clinical development covering multiple potential indications. It focuses on immuno-oncology, an area in which it has clinical and discovery programs, and product and discovery collaborations. The Company seeks to engage third-party collaborators to assist it in developing companion diagnostics for its clinical programs. The Company’s product candidates include FPA008, FPA144 and FP-1039/GSK3052230. The FPA008 is an antibody that inhibits colony stimulating factor-1 (CSF1), receptor (CSF1R). The FPA144 is an antibody that inhibits fibroblast growth factor receptor 2b (FGFR2b). FP-1039 is a protein therapeutic designed to trap and neutralize cancer-promoting fibroblast growth factors (FGFs).